ClinicalTrials.gg
RecruitingNCT06949800Updated Oct 29, 2026

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

A Phase 2 interventional study of EXE-346 Probiotic and Placebo in HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma and Anal HSIL, sponsored by University of California, San Francisco. Recruiting at 2 sites in 2 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of California, San Francisco · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 29, 2026Eligibility revised1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Squamous Intraepithelial Lesions with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Squamous Intraepithelial Lesions · United States.

Planned enrollment
16th of 39
90 · median 48
Started
2026
with 2 others
Phase 2
19 of 44
4 open now
Registered
42nd of 44
by date
Lead sponsor
2 of 44
University of California, San Francisco

Among the 44 studies in Squamous Intraepithelial Lesions with a site in United States, this one is the 16th largest by planned enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2026, is one of 19 in phase 2, and was the 42nd registered.

Squamous Intraepithelial Lesions

104 studies on the registry are indexed under Squamous Intraepithelial Lesions; 36 are open to participants now.

Browse Squamous Intraepithelial Lesions studies →

Open to participants now

7 of the 44 studies in Squamous Intraepithelial Lesions with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Squamous Intraepithelial Lesions studies recruiting now, 11 (48%) set no upper age limit and 11 (48%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Squamous Intraepithelial Lesions with a site in United States, or all of them as a file.
02

Study summary

This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population

Read the detailed description

This is a randomized double-blinded, placebo-controlled trial.

PRIMARY OBJECTIVES:

I. Evaluate regression to no disease among people with HIV (PWH) with anal HSIL at baseline at Week 36.

II. To determine the safety of EXE-346 in PWH.

SECONDARY OBJECTIVES:

I. To evaluate regression to LSIL or normal at Week 36 among PWH with anal HSIL at baseline.

II. To evaluate clearance at Week 36 to HPV-negative in anal swab for type(s) found at the baseline visit in PWH.

EXPLORATORY OBJECTIVES:

I. To determine if changes in the microbiome from baseline to Week 36 correlate with regression of anal HSIL to low grade squamous intraepithelial lesions (LSIL) or normal, or clearance of HPV found at baseline.

Participants will be randomized in a block design used to stratify women or men according to high-risk human papillomavirus (hrHPV) status (HPV16 present or absent in baseline swab). After confirmation of biopsy-proven HSIL, participants will receive sachets of EXE-346 or placebo for up to 3 months (12 weeks) with follow-up visits at 24 weeks and 36 weeks. Participants with HSIL at week 36 may be treated with non-investigational, standard of care, hyfrecation.

03

Conditions studied

  • HSIL, High Grade Squamous Intraepithelial Lesion
  • HPV-Related Squamous Cell Carcinoma
  • Anal HSIL

Keywords

  • HIV
  • Anal intraepithelial neoplasia (AIN) 3
  • p16+ AIN 2
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. -proven anal HSIL (men or women) at a screening visit for C2002, or clinic patients with known untreated HSIL diagnosed within the previous 3 months.

4. At least one focus of anal HSIL must be large enough to be monitored for response, i.e.,not completely removed after the screening biopsy.

5. Total volume of HSIL is less than 50% of the anal canal or perianal region. 6.Must be actively on treatment with effective antiretroviral therapy (ART) regimen for at least three months preceding enrollment (Visit 1, Day 1) at screening for C2002.

7. RNA \<200 copies/ml at baseline. 9. (ECOG) performance status \<=1 ( >= 70%).

10. Participants must meet the following laboratory parameters within 3 months before enrollment:

a. Leukocytes: ≥3,000/mm\^3. b. : ≥1,500/mm\^3. c. : ≥100,000/mm\^3. d. Elevation of (AST), alanine aminotransferase (ALT), or \<=2 times the .

11. Not pregnant or breast feeding and one of the following:

  1. Of non- (i.e. persons aged 60 years or older or who have had a hysterectomy or tubal ligation or are , as defined by no menses for at least 12 months and without an alternative medical cause).
  2. Persons aged less than 60 years of childbearing potential and agree to practice highly effective from initiation of taking EXE-346 or placebo through 14 days after taking the last dose of EXE-346 or placebo. Highly effective methods of contraception include one or more of the following:

i.Male partner who is sterile (medically effective vasectomy) prior to the female participant's entry into the study and is the sole sexual partner for the female participant.

ii.Hormonal (oral, intravaginal, transdermal, implantable or injectable); Progestogen-only hormonal contraceptives without inhibition of ovulation are not considered to be highly effective.

iii. An intrauterine hormone-releasing system. iv. An intrauterine device. v. Bilateral tubal occlusion or removal. vi. Sexual abstinence, only if the participant refrains from heterosexual intercourse from initiation taking EXE-346 or placebo through 14 days after taking the last dose of EXE-346 or placebo and it is the usual lifestyle of the participant.

Exclusion criteria

Exclusion Criteria:

  1. History of any anogenital cancer.
  2. History of inflammatory bowel disease
  3. Presence of untreated cervical HSIL or cervical cancer.
  4. Anal HSIL on clinical examination or that clinicians are concerned for cancer.
  5. Receipt of chemotherapy, radiotherapy or medication in three months preceding enrollment in ULACNet-101 or at the screening visit for ULACNet-102.
  6. Immunosuppression as a result of underlying illness or treatment including:

    1. Use of high dose (>10 mg/day prednisone or equivalent) for >=7 days (inhaled, otic, topical and ophthalmic corticosteroids are permitted).
    2. Primary immune deficiency disease.
    3. Use of synthetic or biologic disease-modifying anti-rheumatic drugs.
    4. History of bone marrow or solid organ transplant.
    5. History of any other or immunosuppressive disease.
  7. Participant initiated a new treatment with antibiotics within the 2 weeks prior to screening or plans to start antibiotic therapy during the study period.
  8. Participant is taking NSAIDs as a long-term treatment (ie, consistent use for at least 4 days/week each month). Acute use of NSAIDs is allowed.
  9. Participant has known to EXE-346 or any product components.
  10. Current known infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  11. Warts so extensive that they preclude the clinician from determining the extent and location of HSIL.
  12. Sustained, manually confirmed, sitting systolic blood pressure >150 mm Hg or \<90 mm Hg or a diastolic blood pressure >95 mm Hg as measured by 3 readings taken 15 minutes apart at screening or Visit 1.
  13. History of significant thrombocytopenia, history of thrombosis with thrombocytopenia (TTS) syndrome or heparin-induced thrombocytopenia.
  14. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
  15. Use of probiotics other than EXE-346 during the study and for a period of two weeks prior to screening.
  16. Participant has participated in any clinical study of an approved or unapproved medicinal product within the 30 days prior to screening.
  17. Any other finding that, in the opinion of the Investigator deems the participant unsuitable for the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Blinded: EXE-346 probiotic

    Participants will be blinded and stratified on gender and according to hrHPV status (HPV16 present or absent in baseline swab). After confirmation of biopsy-proven HSIL, participants will receive sachets of EXE-346 or placebo, with the contents suspended in water and consumed orally twice per day for 3 months (12 weeks) with follow-up visits at 24 and 36 weeks. Participants will undergo High resolution anoscopy (HRA) as a safety check at Visit 3 (12 weeks) and at Visit 4 (24 weeks) to ensure HRA has not progressed to cancer. Biopsies will only be performed if there is any concern for progression. Participants with active HSIL at week 36 will be treated with non-investigational, standard of care, hyfrecation as soon as possible, but within 8 weeks.

    Drug: EXE-346 Probiotic · Procedure: Usual Care High Resolution Anoscopy (HRA)

  • Placebo comparator
    Blinded: Placebo

    Participants will be blinded and stratified on gender and according to hrHPV status (HPV16 present or absent in baseline swab). After confirmation of biopsy-proven HSIL, participants will receive sachets of EXE-346 or placebo, with the contents suspended in water and consumed orally twice per day for 3 months (12 weeks) with follow-up visits at 24 and 36 weeks. Participants will undergo High resolution anoscopy (HRA) as a safety check at Visit 3 (12 weeks) and at Visit 4 (24 weeks) to ensure HRA has not progressed to cancer. Biopsies will only be performed if there is any concern for progression. Participants with active HSIL at week 36 will be treated with non-investigational, standard of care, hyfrecation as soon as possible, but within 8 weeks.

    Drug: Placebo · Procedure: Usual Care High Resolution Anoscopy (HRA)

Interventions

  • DrugProbioticStudies of ProbioticProbiotic pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given as a single-dose, powder packet to mix with water

    Also known as: EXE-346 Probiotic formula, Probiotic

  • DrugPlacebo

    Given as a single-dose, powder packet to mix with water

    Also known as: Blinded Placebo

  • ProcedureUsual Care High Resolution Anoscopy (HRA)

    Non-investigational HRA will be performed

    Also known as: HRA

06

What researchers measure

Primary outcomes

  1. Proportion of participants with no disease present

    No anal disease defined as complete regression of lesions as determined by examination of biopsies obtained at HRA

    Time frame: Up to 36 weeks

  2. Proportion of participants reporting treatment-emergent adverse events

    The frequency of participants reporting adverse events by group will be classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0

    Time frame: Up to 36 weeks

Secondary outcomes

  1. Proportion of participants with demonstrated disease regression

    Regression of HSIL associated with any hrHPV type to LSIL or lower, as determined by examination of biopsies obtained at HRA

    Time frame: Up to 36 weeks

  2. Proportion of participants with HPV-negative status

    The proportion of participants with HPV-negative on anal swab for type(s) found at baseline will be reported.

    Time frame: 1 day

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified information will be shared with study collaborators

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: For the duration of study activities

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Oct 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
Apr 29, 2025
StartActual
Sep 4, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
May 31, 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • University of Puerto Rico Comprehensive Cancer Center · San Juan, Puerto Rico
Show 1 removed
  • University of Puerto Rico Comprehensive Cancer Center · San Juan, Puerto Rico
Oct 29, 2026
Eligibility
4 inclusion criteria edited, 7 removed; 2 exclusion criteria added
What changed in the criteria
Inclusion criteria
  • RemovedParticipant in ULACNet-101 or participant screened specifically for ULACNet-102.
  • EditedBiopsy-proven anal HSIL (men or women) shown as part of participation in the ULACNet-101 study or at a screening visit for ULACNet-102C2002, or clinic patients with known untreated HSIL diagnosed within the previous 3 months.
  • RemovedTotal volume of HSIL is less than 50% of the anal canal or perianal region.
  • Edited5. Total volume of HSIL is less than 50% of the anal canal or perianal region. 6.Must be actively on treatment with effective antiretroviral therapy (ART) regimen for at least three months preceding enrollment (Visit 1, Day 1) in ULACNet-101 or at screening for ULACNet-102C2002.
  • RemovedHIV RNA <200 copies/ml at baseline.
  • RemovedCluster of differentiation 4 (CD4) nadir above 200 cells per microliter (uL)
  • Edited7.HIV RNA <200 copies/ml at baseline. 9.Eastern Cooperative Oncology Group (ECOG) performance status <=1 (Karnofsky >= 70%).
  • RemovedLeukocytes: ≥3,000/mm\^3.
  • RemovedAbsolute neutrophil count: ≥1,500/mm\^3.
  • RemovedPlatelets: ≥100,000/mm\^3.
  • EditedLeukocytes: ≥3,000/mm\^3. b. Absolute neutrophil count: ≥1,500/mm\^3. c. Platelets: ≥100,000/mm\^3. d. Elevation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin <=2 times the upper limit of normal.
Exclusion criteria
  • AddedHistory of inflammatory bowel disease
  • AddedUse of probiotics other than EXE-346 during the study and for a period of two weeks prior to screening.
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    1 site added, 1 site removed
    Show site
    • University of Puerto Rico Comprehensive Cancer Center · San Juan, Puerto Rico
    Show 1 removed
    • University of Puerto Rico Comprehensive Cancer Center · San Juan, Puerto Rico
    Eligibility 4 inclusion criteria edited, 7 removed; 2 exclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • RemovedParticipant in ULACNet-101 or participant screened specifically for ULACNet-102.
    • EditedBiopsy-proven anal HSIL (men or women) shown as part of participation in the ULACNet-101 study or at a screening visit for ULACNet-102C2002, or clinic patients with known untreated HSIL diagnosed within the previous 3 months.
    • RemovedTotal volume of HSIL is less than 50% of the anal canal or perianal region.
    • Edited5. Total volume of HSIL is less than 50% of the anal canal or perianal region. 6.Must be actively on treatment with effective antiretroviral therapy (ART) regimen for at least three months preceding enrollment (Visit 1, Day 1) in ULACNet-101 or at screening for ULACNet-102C2002.
    • RemovedHIV RNA <200 copies/ml at baseline.
    • RemovedCluster of differentiation 4 (CD4) nadir above 200 cells per microliter (uL)
    • Edited7.HIV RNA <200 copies/ml at baseline. 9.Eastern Cooperative Oncology Group (ECOG) performance status <=1 (Karnofsky >= 70%).
    • RemovedLeukocytes: ≥3,000/mm\^3.
    • RemovedAbsolute neutrophil count: ≥1,500/mm\^3.
    • RemovedPlatelets: ≥100,000/mm\^3.
    • EditedLeukocytes: ≥3,000/mm\^3. b. Absolute neutrophil count: ≥1,500/mm\^3. c. Platelets: ≥100,000/mm\^3. d. Elevation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin <=2 times the upper limit of normal.
    Exclusion criteria
    • AddedHistory of inflammatory bowel disease
    • AddedUse of probiotics other than EXE-346 during the study and for a period of two weeks prior to screening.
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06949800
Collaborators
Exegi Pharma, LLC, National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Apr 29, 2025
Start date
Sep 4, 2026
Primary completion
Oct 31, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Ross Jamison
Contact
Ross.Jamison@ucsf.edu
(415) 353-9042
Jenn Marino
Contact
jenn.marino@ucsf.edu
(415) 5141062
Joel Palefsky, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion